Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12051
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ardipradja, Katie | en |
dc.contributor.author | Yeoh, Shinn Dee | en |
dc.contributor.author | Alt, Karen | en |
dc.contributor.author | O'Keefe, Graeme J | en |
dc.contributor.author | Rigopoulos, Angela | en |
dc.contributor.author | Howells, David William | en |
dc.contributor.author | Scott, Andrew M | en |
dc.contributor.author | Peter, Karlheinz | en |
dc.contributor.author | Ackerman, Uwe | en |
dc.contributor.author | Hagemeyer, Christoph E | en |
dc.date.accessioned | 2015-05-16T01:41:47Z | |
dc.date.available | 2015-05-16T01:41:47Z | |
dc.date.issued | 2013-12-18 | en |
dc.identifier.citation | Nuclear Medicine and Biology 2013; 41(3): 229-37 | en |
dc.identifier.govdoc | 24440583 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12051 | en |
dc.description.abstract | Activated platelets are key players in thrombosis and inflammation. We previously generated single-chain antibodies (scFv) against ligand-induced binding sites (LIBS) on the highly abundant platelet glycoprotein integrin receptor IIb/IIIa. The aim of this study was the construction and characterisation of a novel (18)F PET radiotracer based on this antibody.ScFv(anti-LIBS) and control antibody mut-scFv were reacted with N-succinimidyl-4-[(18)F]fluorobenzoate (S[(18)F]FB). Radiolabeled scFv was incubated with in vitro formed platelet clots and injected into mice with FeCl(3) induced thrombus in the left carotid artery. Clots were imaged in the PET scanner and amount of radioactivity measured using an ionization chamber and image analysis. Assessment of vessel injury as well as the biodistribution of the radiolabeled scFv was studied.After incubation with increasing concentrations of (18)F-scFv(anti-LIBS) clots had retained significantly higher amounts of radioactivity compared to clots incubated with radiolabeled (18)F-mut-scFv (13.3 ± 3.8 vs. 3.6 ± 1 KBq, p < 0.05, n = 9, decay corrected). In the in vivo experiments we found an high uptake of the tracer in the injured vessel compared with the non-injured vessel, with 12.6 ± 4.7% injected dose per gram (ID/g) uptake in the injured vessel and 3.7 ± 0.9% ID/g in the non-injured vessel 5 minutes after injection (p < 0.05, n = 6).Our results show that the novel antibody radiotracer (18)F-scFv(anti-LIBS) is useful for the sensitive detection of activated platelets and thrombosis.We describe the first (18)F variant of a scFv(anti-LIBS) against activated platelets. This diagnostic agent could provide a powerful tool for the assessment of acute thrombosis and inflammation in patients in the future. | en |
dc.language.iso | en | en |
dc.subject.other | Antibodies | en |
dc.subject.other | PET/CT | en |
dc.subject.other | Platelets | en |
dc.subject.other | Thrombosis | en |
dc.subject.other | Animals | en |
dc.subject.other | Benzoates.chemistry | en |
dc.subject.other | Blood Coagulation | en |
dc.subject.other | Carotid Artery Thrombosis.pathology.physiopathology.radionuclide imaging | en |
dc.subject.other | Disease Models, Animal | en |
dc.subject.other | Female | en |
dc.subject.other | Fluorine Radioisotopes.diagnostic use | en |
dc.subject.other | Image Processing, Computer-Assisted | en |
dc.subject.other | Mice | en |
dc.subject.other | Mice, Inbred C57BL | en |
dc.subject.other | Platelet Activation | en |
dc.subject.other | Positron-Emission Tomography | en |
dc.subject.other | Single-Chain Antibodies.chemistry.diagnostic use.pharmacokinetics | en |
dc.title | Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Nuclear medicine and biology | en |
dc.identifier.affiliation | Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia | en |
dc.identifier.affiliation | Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia | en |
dc.identifier.affiliation | Central Clinical School, Monash University, Melbourne, Australia | en |
dc.identifier.affiliation | Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia | en |
dc.identifier.affiliation | Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia | en |
dc.identifier.affiliation | The Florey Institute of Neuroscience and Mental Health, Austin Hospital, Melbourne, Australia | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia | en |
dc.identifier.doi | 10.1016/j.nucmedbio.2013.12.006 | en |
dc.description.pages | 229-37 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24440583 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Scott, Andrew M | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.